罕见遗传变异在心力衰竭患者中的作用评估
临床试验中3.4%患者携带致病或可能致病的心肌病基因变异,其中60.2%临床病因为缺血性心脏病。
要点
- TTN蛋白截短变异与心衰显著相关,心脏组成型表达外显子变异OR达4.52。
- 3.4%心衰患者携带致病/可能致病心肌病基因变异,涉及21个基因。
- 携带心肌病基因变异者中60.2%临床病因为缺血性心脏病。
核心结论
- 在主要为缺血性病因的广泛心衰患者中,诊断性孟德尔心肌病变异负荷较对照增加。
- 孟德尔遗传病可能代表心衰等复杂晚发性疾病的重要亚群,与临床表现无关。
研究设计与样本
- 回顾性分析临床试验(CHARM和CORONA)及前瞻性流行病学资源(UK Biobank)。
- 对心衰患者进行全外显子测序,采用基因-based collapsing方法比较罕见有害变异比例。
主要发现
- TTN基因蛋白截短变异显著富集(P=3.35×10-13;OR 2.54;95%CI 1.96-3.31)。
- 限制于心脏组成型表达外显子后OR为4.52(95%CI 3.10-6.68),UK Biobank验证OR为4.97(95%CI 3.94-6.19)。
- 临床试验中201/5916例(3.4%)携带致病或可能致病心肌病基因变异,涉及21个基因。
- 201例中121例(60.2%)临床病因为缺血性心脏病。
- 射血分数保留、中间和降低组诊断率分别为2.6%(20/767)、3.8%(15/392)和3.5%(166/4757)。
临床怎么用
- 对心衰患者应考虑遗传评估,即使临床病因为缺血性心脏病。
- TTN蛋白截短变异应关注心脏组成型表达外显子区域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sequencing studies have identified causal genetic variants for distinct subtypes of heart failure (HF) such as hypertrophic or dilated cardiomyopathy. However, the role of rare, high-impact variants in HF, for which ischemic heart disease is the leading cause, has not been systematically investigated. OBJECTIVE: To assess the contribution of rare variants to all-cause HF with and without reduced left ventricular ejection fraction. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective analysis of clinical trials and a prospective epidemiological resource (UK Biobank). Whole-exome sequencing of patients with HF was conducted from the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) and Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) clinical trials. Data were collected from March 1999 to May 2003 for the CHARM studies and September 2003 to July 2007 for the CORONA study. Using a gene-based collapsing approach, the proportion of patients with HF and controls carrying rare and presumed deleterious variants was compared. The burden of pathogenic variants in known cardiomyopathy genes was also investigated to assess the diagnostic yield. Exome sequencing data were generated between January 2018 and October 2018, and analysis began October 2018 and ended April 2020. MAIN OUTCOMES AND MEASURES: Odds ratios and P values for genes enriched for rare and presumed deleterious variants in either patients with HF or controls and diagnostic yield of pathogenic variants in known cardiomyopathy genes. RESULTS: This study included 5942 patients with HF and 13 156 controls. The mean (SD) age was 68.9 (9.9) years and 4213 (70.9%) were male. A significant enrichment of protein-truncating variants in the TTN gene (P = 3.35 × 10-13; odds ratio, 2.54; 95% CI, 1.96-3.31) that was further increased after restriction to variants in exons constitutively expressed in the heart (odds ratio, 4.52; 95% CI, 3.10-6.68). Validation using UK Biobank data showed a similar enrichment (odds ratio, 4.97; 95% CI, 3.94-6.19 after restriction). In the clinical trials, 201 of 5916 patients with HF (3.4%) had a pathogenic or likely pathogenic cardiomyopathy variant implicating 21 different genes. Notably, 121 of 201 individuals (60.2%) had ischemic heart disease as the clinically identified etiology for the HF. Individuals with HF and preserved ejection fraction had only a slightly lower yield than individuals with midrange or reduced ejection fraction (20 of 767 [2.6%] vs 15 of 392 [3.8%] vs 166 of 4757 [3.5%]). CONCLUSIONS AND RELEVANCE: An increased burden of diagnostic mendelian cardiomyopathy variants in a broad group of patients with HF of mostly ischemic etiology compared with controls was observed. This work provides further evidence that mendelian genetic conditions may represent an important subset of complex late-onset diseases such as HF, irrespective of the clinical presentation.
引用
- Povysil G, Chazara O, Carss KJ, et al. Assessing the Role of Rare Genetic Variation in Patients With Heart Failure. JAMA Cardiol. 2021. PMID: 33326012. doi:10.1001/jamacardio.2020.6500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。